Login / Signup

Alamandine abrogates neutrophil degranulation in atherosclerotic mice.

Analina R Da SilvaSébastien LengletFederico CarboneFabienne BurgerAline RothLuca LiberaleAldo BonaventuraFranco DallegriNikolaos StergiopulosRobson A S SantosFrançois MachRodrigo A Fraga-SilvaFabrizio Montecucco
Published in: European journal of clinical investigation (2017)
These results suggest that treatment with the MrgD agonist alamandine led to a reduced release of neutrophil granule products, potentially interfering with pro-atherosclerotic neutrophil activation.
Keyphrases
  • anti inflammatory
  • type diabetes
  • metabolic syndrome
  • adipose tissue
  • skeletal muscle
  • combination therapy
  • replacement therapy
  • smoking cessation